Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers (NCT04295863)
A Randomized Study Investigating the Pharmacokinetics of Standard Interval Dosing Compared to Extended Interval Dosing of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
🩺 Plain-English Summary (8th-Grade Level)
A randomized research study of drugs nivolumab and pembrolizumab in patients with locally advanced or metastatic cancers. Based on data from earlier studies it appears that the drugs can be given less often then the currently approved schedule. This trial will compare drug levels from the blood from standard interval dosing levels versus taking the drugs less often.
Who can join: Review the eligibility criteria below.
Location: University Of Chicago Medicine Comprehensive Cancer Center — Chicago, Illinois
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- University Of Chicago Medicine Comprehensive Cancer Center — Chicago, Illinois
- SSM Health Cancer Care — Madison, Wisconsin
📞 Contact the Study Coordinator
Phone: (773) 702-1220
Email: PhaseIICRA@medicine.bsd.uchicago.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Cancer
- A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors — Hartford, Connecticut
- Niraparib in Tumors Metastatic to the CNS — Boston, Massachusetts
- Stereotactic Radiotherapy for Oligo-Progressive Metastatic Cancer (The STOP Trial) — Edmonton, Alberta
- A Study of Stereotactic Body Radiotherapy (SBRT) and Surgical Stabilization for People With Cancer That Has Spread to the Bone — Basking Ridge, New Jersey
- An Intervention to Help Patients and Caregivers Manage Stress and Improve Communication Skills When Talking About Cancer — New York, New York
- CSB-321 Ph 1 in Immunotherapy for the Treatment of Cancer — Boston, Massachusetts
Explore by condition: All Metastatic Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.